Washington—A new type of treatment that improved overall survival (OS) in patients with newly diagnosed glioblastoma multiforme (GBM) also may have relevance for other malignancies in which local tumor control is important. The treatment involves a wearable device that generates alternating electric fields to disturb cell mitotic activity, resulting in tumor cell death.
In GBM, the survival advantage of adding this therapy—called tumor treating fields (TTF)—to temozolomide (